RELATED CONTENT
NEWS
- European generics firms, squeezed between innovators and payers, seek diversity
- Generics firms urge EC to help boost sales in EU and emerging markets
- EU reprieve for Actos as CHMP concludes benefits outweigh risks in selected patients
- EMA confirms Champix' positive benefit-risk balance, but will review data in September

